Lycera Corp.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2006-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.lycera.com
Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer
- First Posted Date
- 2018-01-11
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- Lycera Corp.
- Target Recruit Count
- 17
- Registration Number
- NCT03396497
- Locations
- 🇺🇸
Lycera Investigational Site, Seattle, Washington, United States
Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer
Phase 1
Completed
- Conditions
- Cancer
- Interventions
- Drug: LYC-55716
- First Posted Date
- 2016-10-11
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- Lycera Corp.
- Target Recruit Count
- 119
- Registration Number
- NCT02929862
- Locations
- 🇺🇸
Lycera Investigational Site, Fairfax, Virginia, United States
An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis
Phase 2
Completed
- Conditions
- Psoriasis
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2019-04-10
- Lead Sponsor
- Lycera Corp.
- Target Recruit Count
- 33
- Registration Number
- NCT02872285
- Locations
- 🇺🇸
Lycera Investigational Site, Norfolk, Virginia, United States
Safety and Pharmacokinetic Study of LYC-30937 in Subjects With Active Ulcerative Colitis
Phase 1
Completed
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: LYC-30937
- First Posted Date
- 2016-06-29
- Last Posted Date
- 2016-12-14
- Lead Sponsor
- Lycera Corp.
- Target Recruit Count
- 6
- Registration Number
- NCT02818543
- Locations
- ðŸ‡ðŸ‡º
PRA Magyarorszag Kft, Budapest, Hungary
ðŸ‡ðŸ‡ºDRC Ltd., Balatonfured, Hungary
Open-label Extension Study to Assess Safety and Tolerability of LYC-30937-EC in Subjects With Active Ulcerative Colitis
Phase 2
Terminated
- Conditions
- Colitis, Ulcerative
- Interventions
- Drug: LYC-30937-EC
- First Posted Date
- 2016-05-06
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- Lycera Corp.
- Target Recruit Count
- 112
- Registration Number
- NCT02764229
- Locations
- 🇺🇸
Lycera investigational site, San Antonio, Texas, United States
🇷🇸Lycera Investigational Site, Zrenjanin, Serbia
An Efficacy and Safety Study of LYC-30937-EC in Subjects With Active Ulcerative Colitis
Phase 2
Completed
- Conditions
- Colitis, Ulcerative
- Interventions
- Drug: LYC-30937-ECDrug: Placebo
- First Posted Date
- 2016-05-05
- Last Posted Date
- 2019-04-02
- Lead Sponsor
- Lycera Corp.
- Target Recruit Count
- 124
- Registration Number
- NCT02762500
- Locations
- 🇺🇸
Lycera Investigational Site., Houston, Texas, United States
🇺🇸Lycera Investigational Sites, Houston, Texas, United States
🇷🇸Lycera Investigational Site, Zrenjanin, Serbia
© Copyright 2025. All Rights Reserved by MedPath